StreetInsider.com News Articles

Form 10-K Greenwich LifeSciences, For: Dec 31

Mon, 01 Jun 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260601/26584764.html

Form 10-K Greenwich LifeSciences, For: Dec 31

Mon, 01 Jun 2026 16:56:00 -0400

si-local-file:///var/storage/secattach/20260601/26584764.html

Greenwich LifeSciences presents FLAMINGO-01 immune response data

Mon, 01 Jun 2026 08:16:26 -0400

Greenwich LifeSciences Inc. (NASDAQ: GLSI) presented data from its ongoing FLAMINGO-01 Phase III clinical trial at the ASCO Annual Meeting. The company reported preliminary injection site reaction immune response results from the open-label arm of the study evaluating GLSI-100, an immunotherapy designed to prevent breast cancer recurrences.

The trial enrolled 247 non-HLA-A*02 patients who received GLSI-100 treatment. According to the data, patients showed statistically significant increases in injection site reactions over time. Erythema reactions increased from 20.2% of patients after the first vaccination to 55.3% after the fourth, fifth, or sixth vaccination. Induration reactions rose from 14.9% to 34.6% over the

Greenwich LifeSciences presents FLAMINGO-01 immune response data

Mon, 01 Jun 2026 08:16:26 -0400

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026

Mon, 01 Jun 2026 08:15:00 -0400

STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today presents the published abstract and poster from the ASCO Annual Meeting 2026.

The abstract is shown below and the poster being presented today can be seen and downloaded at the bottom of the Phase III clinical trial tab on the Company's website here.

This is the

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at ASCO Meeting 2026

Mon, 01 Jun 2026 08:15:00 -0400

The abstract is shown below and the poster being presented today can be seen and downloaded at the bottom of the Phase III clinical trial tab on the Company's website here.

This is the

Greenwich LifeSciences delays Form 10-K filing due to auditor coordination

Mon, 01 Jun 2026 06:01:27 -0400

Greenwich LifeSciences Inc. (NASDAQ: GLSI) announced that its Form 10-K filing for fiscal year 2025 remains under audit and has been delayed beyond the standard filing deadline.

The company stated that coordination between its current and former auditors has prevented timely filing, as both auditors must agree for the dual auditor filing to proceed. The Form 10-K includes both the 2025 audit by the new auditor and the 2024 audit previously completed by the former auditor.

Greenwich LifeSciences attributed the delays to accounts payable adjustments related to its Phase III clinical trial and increased patient enrollment in Europe during 2024 and 2025.

Greenwich LifeSciences Provides Update Regarding Form 10-K Filing

Mon, 01 Jun 2026 06:00:00 -0400

STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on its Form 10-K filing for the fiscal year ending December 31, 2025.

The Form 10-K for the fiscal year ending December 31, 2025, continues to be audited by our new auditor and we believe it is in the final approval steps. The Form 10-K also includes the 2024 audit

Greenwich LifeSciences Provides Update Regarding Form 10-K Filing

Mon, 01 Jun 2026 06:00:00 -0400

STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided an update on its Form 10-K filing for the fiscal year ending December 31, 2025.

The Form 10-K for the fiscal year ending December 31, 2025, continues to be audited by our new auditor and we believe it is in the final approval steps. The Form 10-K also includes the 2024 audit

Greenwich LifeSciences receives Nasdaq notice for late quarterly filing

Fri, 22 May 2026 16:30:55 -0400

Greenwich LifeSciences Inc. (NASDAQ: GLSI) received notification from Nasdaq on May 20 that the company is not in compliance with listing requirements due to a late quarterly filing, according to a company statement.

The Nasdaq Listing Qualifications Department notified Greenwich that it has not filed its Form 10-Q quarterly report for the three months ended March 31, 2026, violating Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission.

The notice does not immediately affect the listing or trading of Greenwich's common stock, which continues to trade on the Nasdaq Capital Market under the

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Fri, 22 May 2026 16:30:00 -0400

STAFFORD, Texas, May 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) ("Greenwich" or the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designated GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that on May 20, 2026, the Company received notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that, because it has not yet filed its Quarterly Report on Form 10-Q for the three months ended March 31, 2026, the Company is not currently in compliance with

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Fri, 22 May 2026 16:30:00 -0400

Greenwich LifeSciences delays annual filing amid audit completion

Thu, 30 Apr 2026 06:01:45 -0400

Greenwich LifeSciences Inc. (NASDAQ: GLSI) announced that its Form 10-K filing for fiscal year 2025 remains under audit and will be delayed until the end of May 2026.

The clinical-stage biopharmaceutical company stated that auditors are working to reach agreement on final figures, with completion expected alongside the filing of its Form 10-Q for the quarter ending March 31, 2026. The final adjustments focus on accounts payable related to the company's Phase III clinical trial and increased patient enrollment in Europe during 2024 and 2025.

Greenwich LifeSciences reported an unaudited cash balance of approximately $10.5 million as of March 31, 2026, subject

Greenwich LifeSciences Provides Update Regarding Form 10-K Filing